Editorial

A New Dawn

It's a new dawn. It's a new day. These powerful words in one of my favorite songs ("Feeling Good") by...

ADCT-301 – A Novel Antibody-drug Conjugate Against Lymphomas – Moves Into Phase I Clinical...

ADC Therapeutics Sarl (Epalinges, Switzerland), a company involved in the development of antibody-drug conjugates against solid and hematological cancers, has filed an...

Positive Toxicology & Production Data on ADCs Generated with SMARTag™ Technology

Over the last decades antibody drug conjugates have received much attention.  This is, in part, due to their huge...

Immuno-Oncology SEA-CD40 Moves Into Phase I Clinical Trial for Advanced Solid Tumors

Earlier today, Seattle Genetics Inc, announced the initiation of a new Phase I clinical trial of SEA-CD40, which utilizes...

The Business of Bispecific Antibodies: Generating Focused Development Libraries

Bispecific antibodies (BsAb), widely used in the development of anticancer immunotherapy, are proteins capable of simultaneously binding two different...

Sanofi and Catalent Develop Next-Gen ADCs with SMARTag Technology

Catalent Pharma Solutions, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer...

Advancing Immunotherapy and the Future of Care: Nantworks Collaborates with Sorrento Therapeutics and Phoenix...

NantWorks, LLC, a California-based medical technology company and Sorrento Therapeutics, Inc, an oncology company developing new, targeted, treatments for cancer,...

Characterization of Antibody-drug Conjugates by Mass Spectrometry

Therapeutic antibody-drug conjugates or ADCs combine a target specific monoclonal antibody or mAb with the cell-killing activity of a...

Design and Synthesis of Novel Auristatin Analogs with N-terminal Modifications

Auristatins, the structurally related synthetic analogs of the antitumor agent Dolastatin 10, a pentapeptide originally isolated from the sea...
pancreatic cancer cells

Fab’-installed Polymeric Micelles Significantly Improve Efficient Drug Delivery to Solid Tumors

To enhance the efficacy of unconjugated antibodies, researchers have optimized their antitumor activity by conjugating them with radionuclides, toxins,...

FEATURED